H1 FY27 Financial Performance (Rs. in Crores)

Overall H1 Performance (H1 FY27 vs H1 FY26):

  • Operating Revenue: ₹379.05 Cr, up 1.80% from ₹372.36 Cr
  • Operating Profit: ₹78.11 Cr, up 26.23% from ₹61.87 Cr
  • Operating Profit Margin: 20.61% vs 16.62%
  • EBITDA: ₹36.92 Cr, up 39.11% from ₹26.54 Cr
  • EBITDA Margin: 9.74% vs 7.13%
  • PBT: ₹31.98 Cr, up 53.95% from ₹20.87 Cr
  • PAT: ₹22.64 Cr, up 42.25% from ₹15.91 Cr
  • EPS: ₹2.26 vs ₹1.95

Quarterly Performance (Q2 FY27 vs Q1 FY27):

  • Operating Revenue: ₹185.24 Cr vs ₹193.81 Cr (QoQ decline of 4.42%)
  • Operating Profit: ₹39.96 Cr vs ₹38.15 Cr (QoQ growth of 4.75%)
  • Operating Profit Margin: 21.57% vs 19.68%
  • EBITDA: ₹17.55 Cr vs ₹19.36 Cr (QoQ decline of 9.36%)
  • EBITDA Margin: 9.47% vs 9.99%
  • PAT: ₹11.21 Cr vs ₹11.42 Cr (QoQ decline of 1.85%)
  • EPS: ₹1.12 vs ₹1.14

Other Financial Metrics:

  • Interest: ₹0.06 Cr in H1 FY27 vs ₹0.29 Cr in H1 FY26 (decline of 80.71%)
  • Depreciation: ₹4.88 Cr in H1 FY27 vs ₹5.38 Cr in H1 FY26 (decline of 9.15%)
  • Tax: ₹9.34 Cr in H1 FY27 vs ₹4.96 Cr in H1 FY26 (increase of 88.26%)
  • Other Income: ₹3.69 Cr in H1 FY27 vs ₹4.37 Cr in H1 FY26 (decline of 15.61%)

Operational Performance

  • Production Volume: 987 MT in H1 FY27, up 15% from H1 FY26
  • ROCE: 16.5% in H1 FY27, improved by 600 bps from 10.5% in H1 FY26

Business Overview & Strategy

Company Profile: Established in 1989, Anuh Pharma is a major API manufacturer specializing in Macrolides, Anti-TB products, Anti-bacterials, Anti-malarial, Antihypertension, and Corticosteroids.

Market Presence:

  • 360 marketing partners/customers across 72+ countries
  • ~46% of FY26 revenue came from exports
  • Key export geographies: Europe, Mexico, South Africa
  • Part of the INR 8.5 billion SK Group employing ~2,200 people

Growth Strategy: The company chose "margin over volume" in H1 FY27, replacing lower-margin products with higher-value alternatives. Domestic demand offset softer exports. The priority for H2 FY27 is to rebuild exports and deliver 15-20% annual growth.

Infrastructure & Capacity Expansion

Manufacturing Facilities:

  • Total 3 facilities: 2 at Tarapur, 1 R&D facility at Mahape
  • New Tarapur Unit F-10 commissioned on October 20, 2026
  • Total capacity now: 2,975 MTPA (increased by 575 MTPA with new unit)
  • New facility details: 9,520 sq. mtrs land, 575 MTPA capacity, ~69 KL total reactor capacity, 2 API Blocks & 1 Intermediate Block, multi-purpose cGMP API manufacturing

Regulatory Compliance: Facilities have USFDA, EU GMP, WHO pre-qualification approvals. Recent successful USFDA inspection with zero 483 observations in 2026. Zero Liquid Discharge effluent control system implemented.

Product Portfolio & Development

Market Leadership Products: Erythromycin salts, Pyrazinamide, Sulfadoxine, Ambroxol HCL, Gliclazide, Clobetasol Propionate, Betamethasone Dipropionate.

Products Under Development:

  • Bisoprolol Fumarate (Beta Blocker/Anti Hypertension)
  • Brivaracetam (Anticonvulsant/Antiepileptic)
  • Tegoprazan Fumarate (Gastrointestinal Agent)

Corporate Governance

Board of Directors:

  • Mr. Arun Todarwal - Chairman
  • Mr. Bipin N Shah - Vice Chairman
  • Mr. Ritesh B Shah - Joint MD
  • Mr. Vivek B Shah - Joint MD

Senior Management:

  • Mr. Raju Kotadia - CMO - EM
  • Mr. Vinayak Shenoy - CMO - MM
  • Mr. P.N. Rao - GM Quality
  • Mr. Darshan Rampariya - CFO
  • Mr. Manan Vadhan - CS & Compliance Officer
  • Dr. Sanjay Vaidya - GM R&D
  • Mr. Gulshan Sharma - GM Works

Shareholding Pattern

As of October 30, 2026: Promoters hold 60.83%, Public holds 39.17%.

Corporate Social Responsibility

The company engages in various CSR activities including blood donation camps, green initiatives, education support, and sports promotion.